ARTICLE | Product Development
What’s holding back biopharma data science, and how to fix it
A survey by BioCentury and Owkin points to standardization as a top challenge, and highlights the debate on data centralization
March 18, 2022 9:04 PM UTC
Aligning how data are structured and connecting disjointed datasets are keys to unlocking the value of biopharma data science, according to a survey conducted by BioCentury and precision medicine company Owkin Inc. The decision to share data via centralized pools or access it through decentralized methods can be highly dependent on the players involved.
Responses came from 59 individuals who either work directly in biopharma data science (27%), manage individuals or teams of data scientists (31%), partner with data scientists (22%), invest in data science-focused companies (14%) or are considering taking on at least one of these roles (6%)...